Clinical Trial Update: Tenecteplase (TNK) for Loculated Pleural Effusions in Patients With Malignancy [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/Phase 3 trial evaluating Tenecteplase (TNK) for loculated pleural effusions in patients with malignancy was terminated; results were posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Pleural Effusion

Drugs mentioned

• Tenecteplase (TNK) (tenecteplase)

Snippet

Sponsor: Kaiser Permanente | Conditions: Pleural Effusion | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2015-01-06